Accepting R&D Failure
To file, or not to file – that is the question when it comes to IND applications. Companies don’t always make the right choice, but learning when to abandon ship can open the door to potential future gains.
Stephanie Sutton |
Admitting defeat in pharma R&D and terminating a failing project is a hard decision to make – and sometimes companies file for an Investigational New Drug (IND) application despite unpromising data. Why? A group of researchers recently asked this very question and decided to publish an article on the subject to highlight the issue (1). We spoke to one of the authors, Dennis Lendrem, translational research project manager at the University of Newcastle’s Institute of Cellular Medicine, about the problems facing R&D.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.